Lymphocyte infiltration into the intestinal tract in inflammatory bowel disease 
(IBD) is mediated by interaction between α4 integrin and its specific ligands. 
Development of monoclonal antibodies against α4 integrin allowed targeting of 
lymphocyte trafficking into the intestine as a novel therapeutic intervention. 
Natalizumab, vedolizumab, alicaforsen AJM300, rhuMAb β7, CCX282-B, and 
PF-00547,659 are few of monoclonal antibodies that have shown high promise in 
trials with the potential for more attractive benefit:risk ratio than currently 
available therapies. In this review, an attempt is made to underline the 
therapeutic potential and the safety of anti-adhesion molecule treatment in IBD.